^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
neoantigen DNA vaccine
i
Other names: neoantigen DNA vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AstraZeneca, Washington University School of Medicine in St. Louis
Drug class:
Immunostimulant
Related drugs:
3ms
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
P1, N=12, Recruiting, Washington University School of Medicine | Trial completion date: Oct 2028 --> Jan 2030 | Trial primary completion date: Jan 2026 --> Apr 2027
Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH2 mutation • MGMT promoter methylation • IDH wild-type
|
Zynyz (retifanlimab-dlwr) • neoantigen DNA vaccine
6ms
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=6, Active, not recruiting, Washington University School of Medicine | Trial primary completion date: Mar 2028 --> Sep 2027 | Recruiting --> Active, not recruiting | N=20 --> 6 | Trial completion date: Mar 2030 --> Sep 2029
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
carboplatin • Imfinzi (durvalumab) • neoantigen DNA vaccine
11ms
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
P1, N=12, Recruiting, Washington University School of Medicine | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Jan 2025 --> Jan 2026
Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH2 mutation • MGMT promoter methylation
|
Zynyz (retifanlimab-dlwr) • neoantigen DNA vaccine
11ms
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
P1, N=9, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2024 --> Dec 2025
Trial completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH2 mutation
|
rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
over1year
Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=7, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
Enrollment open
|
neoantigen DNA vaccine
over1year
Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=7, Not yet recruiting, Washington University School of Medicine | Trial completion date: Sep 2030 --> Dec 2030 | Trial primary completion date: Oct 2028 --> Jan 2029
Trial completion date • Trial primary completion date
|
neoantigen DNA vaccine
over1year
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
P1, N=9, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH2 mutation
|
rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
almost2years
Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=7, Not yet recruiting, Washington University School of Medicine | N=10 --> 7
Enrollment change
|
neoantigen DNA vaccine
almost2years
Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=10, Not yet recruiting, Washington University School of Medicine | Trial completion date: Jul 2028 --> Sep 2030 | Trial primary completion date: Aug 2026 --> Oct 2028
Trial completion date • Trial primary completion date
|
neoantigen DNA vaccine
almost2years
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (clinicaltrials.gov)
P1, N=18, Terminated, Washington University School of Medicine | Trial completion date: Aug 2023 --> May 2023 | Active, not recruiting --> Terminated; Drugs/equipment unavailable and insufficient funding
Trial completion date • Trial termination
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Imfinzi (durvalumab) • neoantigen DNA vaccine
2years
Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=10, Not yet recruiting, Washington University School of Medicine | Trial completion date: Apr 2028 --> Jul 2028 | Trial primary completion date: May 2026 --> Aug 2026
Trial completion date • Trial primary completion date
|
neoantigen DNA vaccine
2years
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
P1, N=12, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
Enrollment open
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
|
IDH2 mutation • MGMT promoter methylation • IDH wild-type
|
Zynyz (retifanlimab-dlwr) • neoantigen DNA vaccine
Share via
